Testing Push Should Boost Biomerica Sales
<i> Dow Jones</i>
Biomerica Inc. said that sales of one of its EZ Detect products should benefit from a national initiative to increase the number of Americans tested for colorectal cancer.
EZ Detect, which has been approved by the Food and Drug Administration, is a home test to detect hidden blood in the stool, an early warning sign of colorectal cancer.
The Newport Beach company said Thursday that the American Cancer Society and other groups plan to begin a national testing campaign.
The company’s stock rose 18.3% Thursday, or 31 cents a share, to close at $2.
